Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Recurrent/Metastatic Esophageal Squamous Cell Carcinoma
NCT03913182Phase 2Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Apr 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shanghai Chest Hospital. Primary endpoint: Progression-Free Survival at 2.5 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03913182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03913182.